Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression.
Saved in:
| Title: | Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression. |
|---|---|
| Authors: | Kacerova T; Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK., Willemse E; Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.; Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.; Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Basel, Switzerland.; Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland., Oechtering J; Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.; Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.; Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Basel, Switzerland., Radford-Smith DE; Department of Pharmacology, University of Oxford, Oxford, UK., Xiong W; Department of Pharmacology, University of Oxford, Oxford, UK., Sealey M; Department of Pharmacology, University of Oxford, Oxford, UK., Saldana L; Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK., Maleska Maceski A; Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.; Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.; Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Basel, Switzerland., Yeo T; Department of Neurology, National Neuroscience Institute, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore.; Lee Kong Chian School of Medicine (Nanyang Technological University), Singapore, Singapore.; A*STAR Institute of Molecular and Cell Biology, Singapore, Singapore., DeLuca G; Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK., Palace J; Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK., Leppert D; Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.; Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.; Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Basel, Switzerland., Kuhle J; Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.; Multiple Sclerosis Centre, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.; Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital and University of Basel, Basel, Switzerland., Anthony DC; Department of Pharmacology, University of Oxford, Oxford, UK. daniel.anthony@pharm.ox.ac.uk., Probert F; Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK. |
| Source: | Communications medicine [Commun Med (Lond)] 2026 Feb 25; Vol. 6 (1). Date of Electronic Publication: 2026 Feb 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
